Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Cigarette and Cannabis Smoking Effects on GPR15+ Helper T Cell Levels in Peripheral Blood: Relationships with Epigenetic Biomarkers.

Andersen AM, Lei MK, Beach SRH, Philibert RA, Sinha S, Colgan JD.

Genes (Basel). 2020 Jan 30;11(2). pii: E149. doi: 10.3390/genes11020149.

2.

Autoimmunity-associated intronic SNP (rs2281808) detected by a simple phenotypic assay: Unique case or broader opportunity?

Sinha S, Renavikar PS, Crawford MP, Rodgers JW, Tsalikian E, Tansey M, Karandikar NJ.

Clin Immunol. 2019 Jan;198:57-61. doi: 10.1016/j.clim.2018.12.018. Epub 2018 Dec 21.

3.

An autoimmune disease risk SNP, rs2281808, in SIRPG is associated with reduced expression of SIRPγ and heightened effector state in human CD8 T-cells.

Sinha S, Borcherding N, Renavikar PS, Crawford MP, Tsalikian E, Tansey M, Shivapour ET, Bittner F, Kamholz J, Olalde H, Gibson E, Karandikar NJ.

Sci Rep. 2018 Oct 18;8(1):15440. doi: 10.1038/s41598-018-33901-1.

4.

Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen.

Itani FR, Sinha S, Brate AA, Pewe LL, Gibson-Corley KN, Harty JT, Karandikar NJ.

Sci Rep. 2017 May 8;7(1):1519. doi: 10.1038/s41598-017-01771-8.

5.

Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis.

Mohiuddin IH, Pillai V, Baughman EJ, Greenberg BM, Frohman EM, Crawford MP, Sinha S, Karandikar NJ.

Clin Immunol. 2016 May;166-167:12-8. doi: 10.1016/j.clim.2016.05.001. Epub 2016 May 3.

6.

CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis.

Sinha S, Boyden AW, Itani FR, Crawford MP, Karandikar NJ.

Front Immunol. 2015 Dec 10;6:619. doi: 10.3389/fimmu.2015.00619. eCollection 2015. Review.

7.

Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis.

Sinha S, Crawford MP, Ortega SB, Karandikar NJ.

J Mult Scler (Foster City). 2015 Jan;2(1). pii: 1000130.

8.

Immune regulation of multiple sclerosis by CD8+ T cells.

Sinha S, Itani FR, Karandikar NJ.

Immunol Res. 2014 Aug;59(1-3):254-65. doi: 10.1007/s12026-014-8529-9. Review.

9.

Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

Cunnusamy K, Baughman EJ, Franco J, Ortega SB, Sinha S, Chaudhary P, Greenberg BM, Frohman EM, Karandikar NJ.

Clin Immunol. 2014 May-Jun;152(1-2):115-26. doi: 10.1016/j.clim.2014.03.005. Epub 2014 Mar 20.

10.

Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.

Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, Karandikar NJ.

Clin Immunol. 2013 May;147(2):105-19. doi: 10.1016/j.clim.2013.02.015. Epub 2013 Mar 6.

11.

Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.

Burrows GG, Meza-Romero R, Huan J, Sinha S, Mooney JL, Vandenbark AA, Offner H.

Metab Brain Dis. 2012 Jun;27(2):143-9. doi: 10.1007/s11011-012-9289-7. Epub 2012 Mar 7.

12.

RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS.

Sinha S, Miller LM, Subramanian S, Burrows GG, Vandenbark AA, Offner H.

PLoS One. 2011;6(7):e21868. doi: 10.1371/journal.pone.0021868. Epub 2011 Jul 5.

13.

Characterization of human platelet binding of recombinant T cell receptor ligand.

Itakura A, Aslan JE, Sinha S, White-Adams TC, Patel IA, Meza-Romero R, Vandenbark AA, Burrows GG, Offner H, McCarty OJ.

J Neuroinflammation. 2010 Nov 8;7:75. doi: 10.1186/1742-2094-7-75.

14.

RTL therapy for multiple sclerosis: a Phase I clinical study.

Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA.

J Neuroimmunol. 2011 Feb;231(1-2):7-14. doi: 10.1016/j.jneuroim.2010.09.013. Epub 2010 Oct 20.

15.

Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

Sinha S, Miller L, Subramanian S, McCarty OJ, Proctor T, Meza-Romero R, Huan J, Burrows GG, Vandenbark AA, Offner H.

J Neuroimmunol. 2010 Aug 25;225(1-2):52-61. doi: 10.1016/j.jneuroim.2010.04.013. Epub 2010 May 23.

16.

Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barré syndrome in Northern Indian population.

Nyati KK, Prasad KN, Verma A, Singh AK, Rizwan A, Sinha S, Paliwal VK, Pradhan S.

J Neuroimmunol. 2010 Jan 25;218(1-2):116-9. doi: 10.1016/j.jneuroim.2009.10.018. Epub 2009 Nov 13.

PMID:
19913922
17.

Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG.

Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows GG, Grafe M, Linington C, Vandenbark AA, Bernard CC, Offner H.

J Neuroimmune Pharmacol. 2010 Jun;5(2):231-9. doi: 10.1007/s11481-009-9175-1. Epub 2009 Sep 30.

18.

Cell cycle arrest & apoptosis of epithelial cell line by cytolethal distending toxin positive Campylobacter jejuni.

Jain D, Prasad KN, Sinha S, Vishwakarma AL.

Indian J Med Res. 2009 Apr;129(4):418-23.

PMID:
19535837
19.

Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.

Sinha S, Subramanian S, Miller L, Proctor TM, Roberts C, Burrows GG, Vandenbark AA, Offner H.

J Neurosci. 2009 Mar 25;29(12):3816-23. doi: 10.1523/JNEUROSCI.5812-08.2009.

20.

Supplemental Content

Loading ...
Support Center